+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibiotics - Global Strategic Business Report

  • PDF Icon

    Report

  • 266 Pages
  • July 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 358604
The global market for Antibiotics is estimated at US$40.7 Billion in 2023 and is projected to reach US$50.3 Billion by 2030, growing at a CAGR of 3.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Penicillin segment, which is expected to reach US$15.7 Billion by 2030 with a CAGR of a 3.3%. The Cephalosporin segment is also set to grow at 3.8% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $10.9 Billion in 2023, and China, forecasted to grow at an impressive 4.9% CAGR to reach $10.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Antibiotics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Antibiotics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Antibiotics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Laboratories, Inc., Allergan PLC, Aurobindo Pharma Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 209 Featured):

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Shionogi, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Antibiotics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 24: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 26: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 27: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 28: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 29: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 30: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 31: World Antibiotics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 35: USA Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: USA Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: USA 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Canada 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
JAPAN
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Japan 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
CHINA
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: China Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: China 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 53: China Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: China Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: China 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
EUROPE
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 56: Europe Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Europe 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 62: Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Europe 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
FRANCE
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 65: France Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: France Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: France 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 68: France Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: France Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: France 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
GERMANY
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 71: Germany Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Germany 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 74: Germany Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Germany Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Germany 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
ITALY
  • Table 77: Italy Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: Italy 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 80: Italy Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Italy Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: Italy 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 83: UK Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: UK Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: UK 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 86: UK Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: UK Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: UK 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
SPAIN
  • Table 89: Spain Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Spain Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Spain 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 92: Spain Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Spain Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Spain 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
RUSSIA
  • Table 95: Russia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Russia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Russia 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 98: Russia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Russia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Russia 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 101: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 102: Rest of Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 103: Rest of Europe 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 104: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 105: Rest of Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 106: Rest of Europe 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 109: Asia-Pacific 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 111: Asia-Pacific Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 112: Asia-Pacific 16-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2014, 2024 & 2030
  • Table 113: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 114: Asia-Pacific Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 115: Asia-Pacific 16-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2014, 2024 & 2030
AUSTRALIA
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Shionogi, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information